Cargando…

Campylobacter sp.: Pathogenicity factors and prevention methods—new molecular targets for innovative antivirulence drugs?

ABSTRACT: Infections caused by bacterial species from the genus Campylobacter are one of the four main causes of strong diarrheal enteritis worldwide. Campylobacteriosis, a typical food-borne disease, can range from mild symptoms to fatal illness. About 550 million people worldwide suffer from campy...

Descripción completa

Detalles Bibliográficos
Autores principales: Kreling, Vanessa, Falcone, Franco H., Kehrenberg, Corinna, Hensel, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662028/
https://www.ncbi.nlm.nih.gov/pubmed/33185702
http://dx.doi.org/10.1007/s00253-020-10974-5
_version_ 1783609313209614336
author Kreling, Vanessa
Falcone, Franco H.
Kehrenberg, Corinna
Hensel, Andreas
author_facet Kreling, Vanessa
Falcone, Franco H.
Kehrenberg, Corinna
Hensel, Andreas
author_sort Kreling, Vanessa
collection PubMed
description ABSTRACT: Infections caused by bacterial species from the genus Campylobacter are one of the four main causes of strong diarrheal enteritis worldwide. Campylobacteriosis, a typical food-borne disease, can range from mild symptoms to fatal illness. About 550 million people worldwide suffer from campylobacteriosis and lethality is about 33 million p.a. This review summarizes the state of the current knowledge on Campylobacter with focus on its specific virulence factors. Using this knowledge, multifactorial prevention strategies can be implemented to reduce the prevalence of Campylobacter in the food chain. In particular, antiadhesive strategies with specific adhesion inhibitors seem to be a promising concept for reducing Campylobacter bacterial load in poultry production. Antivirulence compounds against bacterial adhesion to and/or invasion into the host cells can open new fields for innovative antibacterial agents. Influencing chemotaxis, biofilm formation, quorum sensing, secretion systems, or toxins by specific inhibitors can help to reduce virulence of the bacterium. In addition, the unusual glycosylation of the bacterium, being a prerequisite for effective phase variation and adaption to different hosts, is yet an unexplored target for combating Campylobacter sp. Plant extracts are widely used remedies in developing countries to combat infections with Campylobacter. Therefore, the present review summarizes the use of natural products against the bacterium in an attempt to stimulate innovative research concepts on the manifold still open questions behind Campylobacter towards improved treatment and sanitation of animal vectors, treatment of infected patients, and new strategies for prevention. KEY POINTS: • Campylobacter sp. is a main cause of strong enteritis worldwide. • Main virulence factors: cytolethal distending toxin, adhesion proteins, invasion machinery. • Strong need for development of antivirulence compounds.
format Online
Article
Text
id pubmed-7662028
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-76620282020-11-13 Campylobacter sp.: Pathogenicity factors and prevention methods—new molecular targets for innovative antivirulence drugs? Kreling, Vanessa Falcone, Franco H. Kehrenberg, Corinna Hensel, Andreas Appl Microbiol Biotechnol Mini-Review ABSTRACT: Infections caused by bacterial species from the genus Campylobacter are one of the four main causes of strong diarrheal enteritis worldwide. Campylobacteriosis, a typical food-borne disease, can range from mild symptoms to fatal illness. About 550 million people worldwide suffer from campylobacteriosis and lethality is about 33 million p.a. This review summarizes the state of the current knowledge on Campylobacter with focus on its specific virulence factors. Using this knowledge, multifactorial prevention strategies can be implemented to reduce the prevalence of Campylobacter in the food chain. In particular, antiadhesive strategies with specific adhesion inhibitors seem to be a promising concept for reducing Campylobacter bacterial load in poultry production. Antivirulence compounds against bacterial adhesion to and/or invasion into the host cells can open new fields for innovative antibacterial agents. Influencing chemotaxis, biofilm formation, quorum sensing, secretion systems, or toxins by specific inhibitors can help to reduce virulence of the bacterium. In addition, the unusual glycosylation of the bacterium, being a prerequisite for effective phase variation and adaption to different hosts, is yet an unexplored target for combating Campylobacter sp. Plant extracts are widely used remedies in developing countries to combat infections with Campylobacter. Therefore, the present review summarizes the use of natural products against the bacterium in an attempt to stimulate innovative research concepts on the manifold still open questions behind Campylobacter towards improved treatment and sanitation of animal vectors, treatment of infected patients, and new strategies for prevention. KEY POINTS: • Campylobacter sp. is a main cause of strong enteritis worldwide. • Main virulence factors: cytolethal distending toxin, adhesion proteins, invasion machinery. • Strong need for development of antivirulence compounds. Springer Berlin Heidelberg 2020-11-13 2020 /pmc/articles/PMC7662028/ /pubmed/33185702 http://dx.doi.org/10.1007/s00253-020-10974-5 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Mini-Review
Kreling, Vanessa
Falcone, Franco H.
Kehrenberg, Corinna
Hensel, Andreas
Campylobacter sp.: Pathogenicity factors and prevention methods—new molecular targets for innovative antivirulence drugs?
title Campylobacter sp.: Pathogenicity factors and prevention methods—new molecular targets for innovative antivirulence drugs?
title_full Campylobacter sp.: Pathogenicity factors and prevention methods—new molecular targets for innovative antivirulence drugs?
title_fullStr Campylobacter sp.: Pathogenicity factors and prevention methods—new molecular targets for innovative antivirulence drugs?
title_full_unstemmed Campylobacter sp.: Pathogenicity factors and prevention methods—new molecular targets for innovative antivirulence drugs?
title_short Campylobacter sp.: Pathogenicity factors and prevention methods—new molecular targets for innovative antivirulence drugs?
title_sort campylobacter sp.: pathogenicity factors and prevention methods—new molecular targets for innovative antivirulence drugs?
topic Mini-Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662028/
https://www.ncbi.nlm.nih.gov/pubmed/33185702
http://dx.doi.org/10.1007/s00253-020-10974-5
work_keys_str_mv AT krelingvanessa campylobactersppathogenicityfactorsandpreventionmethodsnewmoleculartargetsforinnovativeantivirulencedrugs
AT falconefrancoh campylobactersppathogenicityfactorsandpreventionmethodsnewmoleculartargetsforinnovativeantivirulencedrugs
AT kehrenbergcorinna campylobactersppathogenicityfactorsandpreventionmethodsnewmoleculartargetsforinnovativeantivirulencedrugs
AT henselandreas campylobactersppathogenicityfactorsandpreventionmethodsnewmoleculartargetsforinnovativeantivirulencedrugs